OVARIAN CARCINOMA, RECURRENT
Clinical trials for OVARIAN CARCINOMA, RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOMA, RECURRENT trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOMA, RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for ovarian cancer: targeted drug takes on resistant tumors
Disease control Recruiting nowThis study tests a new drug, trastuzumab deruxtecan (T-DXd), in people with recurrent ovarian cancer whose tumors have stopped responding to PARP inhibitors. T-DXd targets a protein called HER2 found on some cancer cells. The trial compares T-DXd to standard chemotherapy to see w…
Matched conditions: OVARIAN CARCINOMA, RECURRENT
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
Immune cell therapy takes on recurrent ovarian cancer
Disease control Recruiting nowThis early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to f…
Matched conditions: OVARIAN CARCINOMA, RECURRENT
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 18, 2026 11:59 UTC